• 1
    Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991; 5: 1806-1814.
  • 2
    Nakamura M, Abe Y, Tokunaga T. Pathological significance of vascular endothelial growth factor A isoform expression in human cancer. Pathol Int. 2002; 52: 331-339.
  • 3
    Cohen T, Gitay-Goren H, Sharon R, et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem. 1995; 270: 11322-11326.
  • 4
    Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A. 1997; 94: 12081-12087.
  • 5
    Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92: 735-745.
  • 6
    Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999; 35: 1089-1093.
  • 7
    Lee TH, Bolontrade MF, Worth LL, Guan H, Ellis LM, Kleinerman ES. Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. Int J Cancer. 2006; 119: 839-846.
  • 8
    Zhou Z, Reddy K, Guan H, Kleinerman ES. VEGF, but not VEGF, stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo. Mol Cancer Res. 2007; 5: 1125-1132.
  • 9
    Guan H, Zhou Z, Wang H, Jia SF, Liu W, Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res. 2005; 11: 2662-2669.
  • 10
    Maniatis T, Tasic B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature. 2002; 418: 236-243.
  • 11
    Jung DJ, Na SY, Na DS, Lee JW. Molecular cloning and characterization of CAPER, a novel coactivator of activating protein-1 and estrogen receptors. J Biol Chem. 2002; 277: 1229-1234.
  • 12
    Dowhan DH, Hong EP, Auboeuf D, et al. Steroid hormone receptor coactivation and alternative RNA splicing by U2AF65-related proteins CAPERalpha and CAPERbeta. Mol Cell. 2005; 17: 429-439.
  • 13
    Wiznerowicz M, Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol. 2003; 77: 8957-8961.
  • 14
    Guan H, Zhou Z, Gallick GE, et al. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther. 2008; 7: 1807-1816.
  • 15
    Duan X, Guan H, Cao Y, Kleinerman ES. Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors. Cancer. 2009; 115: 13-22.
  • 16
    Krussel JS, Behr B, Milki AA, Hirchenhain J, Wen Y, Bielfeld P. Vascular endothelial growth factor (VEGF) mRNA splice variants are differentially expressed in human blastocysts. Mol Hum Reprod. 2001; 7: 57-63.
  • 17
    Rennel E, Waine E, Guan H, et al. The endogenous anti- angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008; 98: 1250-1257.
  • 18
    Zygalaki E, Stathopoulou A, Kroupis C, et al. Real-time reverse transcription-PCR quantification of vascular endothelial growth factor splice variants. Clin Chem. 2005; 51: 1518-1520.
  • 19
    Yang L, Chansky HA, Hickstein DD. EWS-FLI-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing. J Biol Chem. 2000; 275: 37612-37618.
  • 20
    Nagano A, Ohno T, Shimizu K, et al. EWS/FLI-1 chimeric fusion gene up-regulates vascular endothelial growth factor-A. Int J Cancer. 2010; 15: 2790-2798.
  • 21
    Fuchs B, Inwards CY, Janknecht R. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res. 2004; 10: 1344-1353.
  • 22
    Hazelton D, Nicosia RF, Nicosia SV. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin Cancer Res. 1999; 5: 823-829.
  • 23
    Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000; 60: 2898-2905.
  • 24
    Dvorak HF, Sioussat TM, Brown LF, et al. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991; 174: 1275-1278.
  • 25
    Senger DR, Van de Water L, Brown LF, et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Met Rev. 1993; 12: 303-324.
  • 26
    Reddy K, Zhou Z, Jia SF, et al. Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. Int J Cancer. 2008; 123: 831-837.
  • 27
    Reddy K, Zhou Z, Jia S-F, Kleinerman ES. Specific bone marrow subsets differentiate into endothelial cells and pericytes and contribute to tumor vessel formation in Ewing's sarcoma. Mol Cancer Res. 2008; 6: 929-936.
  • 28
    Reddy K, Cao Y, Zhou Z, Yu L, Jia S-F, Kleinerman ES. VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature. Angiogenesis. 2008; 11: 257-267.
  • 29
    Grunstein J, Masbad JJ, Hickey R, Giordano F, Johnson RS. Isoforms of vascular endothelial growth factor act in a coordinate fashion to recruit and expand tumor vasculature. Mol Cell Biol. 2000; 20: 7282-7291.
  • 30
    Yu JL, Rak JW, Klement G, Kerbel RS. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Res. 2002; 62: 1838-1846.
  • 31
    Tozer GM, Akerman S, Cross NA, et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res. 2008; 68: 2301-2311.
  • 32
    Uren A, Toretsky JA. Ewing's sarcoma oncoprotein EWS- FLI1: the perfect target without a therapeutic agent. Future Oncol. 2005; 1: 521-528.
  • 33
    Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett. 2007; 254: 1-10.
  • 34
    Smith R, Owen LA, Trem DJ, et al. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma. Cancer Cell. 2006; 9: 405-416.
  • 35
    Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004; 24: 7275-7283.
  • 36
    Zhang D, Paley AJ, Childs G. The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem. 1998; 273: 18086-18091.
  • 37
    Knoop LL, Baker SJ. The splicing factor U1C represses EWS/FLI-mediated transactivation. J Biol Chem. 2000; 275: 24865-24871.
  • 38
    Zhang J, Hu S, Schofield DE, Sorensen PH, Triche TJ. Selective usage of D-type cyclins by Ewing's tumors and rhabdomyosarcomas. Cancer Res. 2004; 64: 6026-6034.